18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
There's good news and bad news if you own shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) . The good news is that the biotech stock is up around 25% since the end of July. The bad news is that Alnylam is still down 35% year-to-date, even with that rebound. Ouch. Has Wall Street soured on Alnylam? Not at all. Of the 21 analysts who have rated the stock over the last three months, 18 recommended it as a "buy" or "strong buy." Here's why I think these analysts are right to be bullish about Alnylam. Image source: Getty Images. Continue reading